Master Agreements

Master Agreements are agreements that embody agreed-upon terms and conditions of a basic relationship between the University and a sponsor.

Once a Master Agreement is in place, an "addendum" or "study letter" is typically generated for each new study to be done under the Master Agreement. The Addendum sets forth the items particular to a certain study such as dollar amount, protocol name, and principal investigator. These Addenda are "attached" to the Master Agreement. This alleviates the need to negotiate the main terms of the agreement, as the majority of the terms are agreed upon and only the particulars need to be negotiated.

We currently have many Master Agreements in place and the UC Office of the President is working on several more. When dealing with the following sponsors, please inform them to use our Master Agreement:

  • Abbott
  • Abbott Vascular (Abbott Device Subsidiaries)
  • AbbVie
  • Aimmune Therapeutics
  • Alexion
  • Alkermes
  • Allergan
  • Alpha Oncology
  • ArcherDX
  • Arcus Biosciences
  • Amgen
  • Astellas
  • AstraZeneca
  • Atara Biotherapeutics (Template agreement)
  • Bayer
  • Biogen – IDEC
  • Boehringer Ingelheim
  • Bioverativ Therapeutics
  • Bristol Meyers Squibb
  • Clovis
  • Cook
  • Eli Lilly
  • EMD Serono
  • Erasca, Inc.
  • Geltex/Genzyme
  • Genentech
  • Gilead
  • GOG Foundation
  • Heron Therapeutics
  • Macrogenics
  • Merck
  • Novartis
  • Opko Biologics
  • Pfizer
  • Pharmacyclics
  • Pharm-Olam
  • Philips (Investigator-initiated studies)
  • Schering-Plough
  • Seattle Genetics
  • Teva
  • Tocagen
  • TG Therapeutics
  • UCB Biosciences
  • Viracta

The University of California has also adopted the Accelerated Clinical Trial Agreement (ACTA).  The ACTA provides a standardized template for industry-sponsored, multi-center studies thus streamlining the contracting process.

As of 08/23/2021

News & Announcements

View More